肝硬化患者药物清除率降低的机制。 - Suppr

Suppr

超能文献

Mechanism for reduced drug clearance in patients with cirrhosis.

作者信息

Pessayre D, Lebrec D, Descatoire V, Peignoux M, Benhamou J P

出版信息

Gastroenterology. 1978 Mar;74(3):566-71.

PMID:631487

Abstract

摘要

相似文献

Mechanism for reduced drug clearance in patients with cirrhosis.肝硬化患者药物清除率降低的机制。

Gastroenterology. 1978 Mar;74(3):566-71.

Pharmacokinetic study on the hepatic uptake of indocyanine green in cirrhotic patients.肝硬化患者肝脏摄取吲哚菁绿的药代动力学研究。

Am J Gastroenterol. 1985 Oct;80(10):801-6.

Simultaneous measurement of effective hepatic blood flow and systemic circulation.有效肝血流量与体循环的同步测量。

Hepatogastroenterology. 2000 Nov-Dec;47(36):1669-74.

[Theophylline pharmacokinetics in patients with liver diseases with reference to estimated hepatic blood flow].

Rinsho Byori. 1991 Oct;39(10):1093-7.

[Liver metabolism of indocyanine green and aminopyrine in liver cirrhosis: relations with functioning liver cell mass].[肝硬化患者肝脏中吲哚菁绿和氨基比林的代谢：与功能性肝细胞量的关系]

Minerva Med. 1988 Dec;79(12):1035-41.

[Hepatic blood flow, portal hypertension and liver failure in patients with alcoholic cirrhosis (author's transl)].

Arch Fr Mal App Dig. 1973 Sep;62(6):465-71.

Indocyanine green clearance following single and chronic cimetidine doses.

Res Commun Chem Pathol Pharmacol. 1984 May;44(2):323-6.

Half-life time or clearance of indocyanine green in patients with liver disease.

Hepatogastroenterology. 1982 Apr;29(2):55-7.

Effect of somatostatin on liver blood flow and liver metabolic activity in patients with cirrhosis.

Scand J Clin Lab Invest. 1987 Nov;47(7):667-72.

Verapamil pharmacokinetics and liver function in patients with cirrhosis.

Int J Clin Pharmacol Res. 1988;8(2):123-6.

引用本文的文献

Development and Evaluation of a Physiologically Based Pharmacokinetic Drug-Disease Model of Propranolol for Suggesting Model Informed Dosing in Liver Cirrhosis Patients.开发和评估普萘洛尔基于生理学的药代动力学药物-疾病模型，以建议肝硬化患者的模型指导剂量。

Drug Des Devel Ther. 2021 Mar 17;15:1195-1211. doi: 10.2147/DDDT.S297981. eCollection 2021.

Imaging-based vascular-related biomarkers for early detection of acetaminophen-induced liver injury.基于影像学的血管相关生物标志物用于早期检测对乙酰氨基酚诱导的肝损伤。

Theranostics. 2020 May 18;10(15):6715-6727. doi: 10.7150/thno.44900. eCollection 2020.

LRH1-driven transcription factor circuitry for hepatocyte identity: Super-enhancer cistromic analysis.LRH1 驱动的肝细胞身份转录因子回路：超级增强子顺式作用元件分析。

EBioMedicine. 2019 Feb;40:488-503. doi: 10.1016/j.ebiom.2018.12.056. Epub 2019 Jan 9.

Liver-enriched transcription factor expression relates to chronic hepatic failure in humans.肝脏富集转录因子的表达与人类慢性肝衰竭相关。

Hepatol Commun. 2018 Mar 23;2(5):582-594. doi: 10.1002/hep4.1172. eCollection 2018 May.

Indocyanine green kinetics to assess liver function: Ready for a clinical dynamic assessment in major liver surgery?用于评估肝功能的吲哚菁绿动力学：准备好在大型肝脏手术中进行临床动态评估了吗？

World J Hepatol. 2016 Mar 8;8(7):355-67. doi: 10.4254/wjh.v8.i7.355.

Resetting the transcription factor network reverses terminal chronic hepatic failure.重置转录因子网络可逆转终末期慢性肝衰竭。

J Clin Invest. 2015 Apr;125(4):1533-44. doi: 10.1172/JCI73137. Epub 2015 Mar 16.

The microenvironment in hepatocyte regeneration and function in rats with advanced cirrhosis.大鼠晚期肝硬化中肝细胞再生和功能的微环境。

Hepatology. 2012 May;55(5):1529-39. doi: 10.1002/hep.24815. Epub 2012 Apr 4.

Pharmacokinetics of opioids in liver disease.阿片类药物在肝脏疾病中的药代动力学。

Clin Pharmacokinet. 1999 Jul;37(1):17-40. doi: 10.2165/00003088-199937010-00002.

Lidocaine and monoethylglycinexylidide serum determinations to analyze liver function of cirrhotic patients after oral administration.

Dig Dis Sci. 1999 Apr;44(4):789-95. doi: 10.1023/a:1026630313038.

Liver metabolic zonation and hepatic microcirculation in carbon tetrachloride-induced experimental cirrhosis.四氯化碳诱导的实验性肝硬化中的肝脏代谢分区与肝微循环

Dig Dis Sci. 1997 Jan;42(1):167-77. doi: 10.1023/a:1018813911469.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验